EKSO (Ekso Bionics Holdings) Moat Score: 3/10 (As of Jul. 03, 2026)


EKSO Ekso Bionics Holdings Inc EKSO
32 GF Score
Price $11.65
GF Value $4.36
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Ekso Bionics Holdings Moat Score?

Ekso Bionics Holdings EKSO -0.42% 32 Moat Score is 3 as of Jul. 03, 2026. GuruFocus rates EKSO with a GF Score™ of 32/100 and a GF Value™ of $4.36 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Ekso Bionics Holdings ranks better than 75.89% on this metric.

Ekso Bionics Holdings has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Ekso Bionics Holdings has No Moat: Ekso Bionics Holdings Inc has some innovative technology but lacks significant market share, brand strength, and customer switching costs, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Ekso Bionics Holdings might have No Moat - Very weak/transient advantages.

Ekso Bionics Holdings  (NAS:EKSO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Ekso Bionics Holdings Moat Score Related Terms

EKSO vs POCI, HBIO, NEPH: Moat Score Comparison

For the Medical Instruments & Supplies subindustry, Ekso Bionics Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ekso Bionics Holdings Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ekso Bionics Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Ekso Bionics Holdings's Moat Score falls into.


EKSO
32GF Score
Ekso Bionics Holdings Inc EKSO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Ekso Bionics Holdings (EKSO) has a Moat Score of 3 as of Jul. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Ekso Bionics Holdings ranks #204 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 24.1%.
Is Ekso Bionics Holdings' Moat Score too high?
Ekso Bionics Holdings' current Moat Score is 3. Based on the distribution chart, Ekso Bionics Holdings ranks #204 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Ekso Bionics Holdings has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ekso Bionics Holdings' Moat Score compare to POCI and HBIO?
According to the Medical Devices & Instruments industry distribution chart, Ekso Bionics Holdings ranks #204 out of 846 companies for Moat Score. This places Ekso Bionics Holdings in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Ekso Bionics Holdings's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ekso Bionics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ekso Bionics Holdings (EKSO) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.36, compared to a current price of $11.65 — trading 167.2% above its estimated fair value. The current Moat Score is 3. Ekso Bionics Holdings' overall GF Score™ is 32/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Ekso Bionics Holdings (EKSO), the current Moat Score is 3 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ekso Bionics Holdings (EKSO) Overvalued in 2026?

Based on GuruFocus' analysis, Ekso Bionics Holdings stock appears to be overvalued. The current stock price of $11.65 is trading 167.2% above its estimated GF Value™ of $4.36. GuruFocus considers Ekso Bionics Holdings to be Significantly Overvalued.

Key valuation signals for EKSO:

  • Moat Score: 3
  • GF Value™: $4.36 vs. price of $11.65 (167.2% above fair value)
  • GF Score™: 32/100 with 10 warning signs

No single metric tells the full story. See the EKSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ekso Bionics Holdings Business Description

Address 101 Glacier Point, Suite A, San Rafael, CA, USA, 94901
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
32GF Score

Get the complete analysis for EKSO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.65
Price
$4.36
GF Value